Catalyst gains FDA approval for reverse shoulder system

Patsy Newitt -   Print  | Email

Catalyst OrthoScience received 510(k) clearance from the FDA to market its reverse shoulder system and expects to commercially launch the shoulder system later this year. 

The reverse shoulder system is designed for patients experiencing severe shoulder arthritis coinciding with a deficient rotator cuff, according to a March 17 press release by the company. 

Reverse shoulder arthroplasty is estimated to encompass more than 60 percent of the shoulder market. The reverse shoulder system's single-tray arthroplasty system will streamline procedures, making them easier and more efficient. 

The commercial launch of the reverse shoulder system will expand the company's arthroplasty options, which include its CSR Total Shoulder System. 

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.